X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (241) 241
female (230) 230
index medicus (219) 219
low-grade (170) 170
ovarian neoplasms - pathology (160) 160
oncology (157) 157
ovarian cancer (144) 144
cancer (142) 142
pathology (108) 108
ovarian neoplasms - genetics (107) 107
middle aged (106) 106
adult (92) 92
aged (85) 85
carcinoma (84) 84
tumors (83) 83
cystadenocarcinoma, serous - pathology (81) 81
obstetrics & gynecology (80) 80
mutation (75) 75
expression (60) 60
prognosis (58) 58
borderline tumors (55) 55
low-grade serous carcinoma (53) 53
neoplasm staging (53) 53
cystadenocarcinoma, serous - genetics (46) 46
immunohistochemistry (46) 46
research (46) 46
aged, 80 and over (45) 45
genetic aspects (45) 45
neoplasm grading (45) 45
mutations (43) 43
ovarian neoplasms - metabolism (43) 43
chemotherapy (42) 42
survival (42) 42
obstetrics and gynecology (39) 39
p53 (39) 39
analysis (38) 38
serous carcinoma (38) 38
kras (37) 37
article (36) 36
ovary (36) 36
pathogenesis (36) 36
endocrine system diseases (34) 34
hematology, oncology and palliative medicine (34) 34
young adult (34) 34
ovarian carcinoma (33) 33
proto-oncogene proteins b-raf - genetics (32) 32
surgery (32) 32
women (31) 31
braf (30) 30
ovarian neoplasms - drug therapy (28) 28
carcinoma, ovarian epithelial (27) 27
care and treatment (27) 27
braf mutation (26) 26
carcinoma - pathology (26) 26
ovarian neoplasms - therapy (26) 26
cell biology (25) 25
female genital diseases and pregnancy complications (25) 25
neoplasms, glandular and epithelial - pathology (25) 25
carcinomas (24) 24
gene expression (24) 24
ovarian neoplasms - mortality (24) 24
retrospective studies (24) 24
animals (23) 23
neoplasms (23) 23
proteins (23) 23
adolescent (22) 22
development and progression (22) 22
diagnosis (22) 22
mutational analysis (22) 22
neoplasms, glandular and epithelial - genetics (22) 22
fallopian-tube (21) 21
neoplasm invasiveness (21) 21
ovarian neoplasms - classification (21) 21
gene mutations (20) 20
health aspects (20) 20
carcinoma - genetics (19) 19
gene expression regulation, neoplastic (19) 19
ovarian neoplasms - diagnosis (19) 19
studies (19) 19
cystadenocarcinoma, serous - metabolism (18) 18
medicine & public health (18) 18
metastasis (18) 18
peritoneal neoplasms - pathology (18) 18
ras proteins - genetics (18) 18
serous borderline tumor (18) 18
survival rate (18) 18
dna mutational analysis (17) 17
gene-expression (17) 17
proto-oncogene proteins - genetics (17) 17
proto-oncogene proteins p21 (17) 17
tumor proteins (17) 17
carcinogenesis (16) 16
cystadenocarcinoma, serous - drug therapy (16) 16
follow-up studies (16) 16
high-grade serous carcinoma (16) 16
intraepithelial carcinoma (16) 16
kinases (16) 16
medical prognosis (16) 16
patterns (16) 16
peritoneum (16) 16
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Gynecologic Oncology, ISSN 0090-8258, 2016, Volume 143, Issue 2, pp. 433 - 438
Journal Article
Cancer, ISSN 0008-543X, 02/2013, Volume 119, Issue 3, pp. 548 - 554
Journal Article
Gynecologic Oncology, ISSN 0090-8258, 2016, Volume 140, Issue 3, pp. 457 - 462
Journal Article
ANTICANCER RESEARCH, ISSN 0250-7005, 10/2019, Volume 39, Issue 10, pp. 5617 - 5621
Background/Aim: Involvement of lymph nodes (LNs) and their surgical resection in low-grade ovarian cancer remains a field of discussion. The aim of this study... 
WOMEN | lymph-node | LYMPHADENECTOMY | ONCOLOGY | metastasis | PREDICTORS | Low-grade ovarian cancer | lymphatic spread | CARCINOMA | TUMORS | Lymphatic system | Ovarian carcinoma | Gynecology | Metastasis | Obstetrics | Nodes | Lymph nodes | Ovarian cancer | Incidence | Metastases | Surgery | Aorta | Cancer | Lymph
Journal Article
Current Treatment Options in Oncology, ISSN 1527-2729, 11/2018, Volume 19, Issue 11, pp. 1 - 6
Low-grade serous ovarian cancer (LGSOC) is a rare subtype of ovarian cancer, accounting for approximately 10% of cases of serous ovarian cancer. Patients... 
MEK | Medicine & Public Health | Gynecologic cancer, rare tumors | Targeted therapy | Oncology | KRAS | BRAF | Low-grade serous ovarian cancer | MAPK | Ovarian cancer | Hormonal therapy | Bevacizumab | BORDERLINE TUMORS | FEATURES | WOMEN | PERITONEAL CANCER | THERAPY | ONCOLOGY | MUTATIONS | CARCINOMA | Care and treatment | Cancer patients | Research | Health aspects | Cancer | Index Medicus
Journal Article
Gynecologic Oncology Reports, ISSN 2352-5789, 05/2019, Volume 28, pp. 26 - 28
Low-grade serous ovarian cancer represents a minority of ovarian cancers and has distinctive features from high grade epithelial ovarian cancer. While less... 
Low-grade serous ovarian cancer | MEK-inhibitor | Targeted therapy
Journal Article
Hematology/Oncology Clinics of North America, ISSN 0889-8588, 12/2018, Volume 32, Issue 6, pp. 929 - 942
The 5 main non–high grade serous epithelial ovarian cancers (clear cell, low grade endometrioid, low grade serous, mucinous, and carcinosarcoma) are discrete... 
Clear cell | Mucinous | Pathogenesis | Carcinosarcoma | Genomics | Endometrioid | Low grade serous | Ovarian cancer | TUMOR-SUPPRESSOR GENE | CARCINOSARCOMAS | BORDERLINE TUMORS | MUCINOUS TUMORS | NRAS | ONCOLOGY | MUTATIONAL LANDSCAPE | HEMATOLOGY | CARCINOMA | EXPRESSION
Journal Article
International Journal of Clinical and Experimental Medicine, ISSN 1940-5901, 07/2017, Volume 10, Issue 7, pp. 10790 - 10797
Objective: To investigate the therapeutic effect of secondary cytoreductive surgery in the patients with low grade serous ovarian cancer and to analyze the... 
Low-grade serous cancer | Gross residua | Secondary cytoreductive surgery | Overall survival | Disease-free survival | SURVIVAL | TRIAL | MEDICINE, RESEARCH & EXPERIMENTAL | secondary cytoreductive surgery | disease-free survival | gross residua | overall survival | INDEX
Journal Article
Journal Article
American Journal of Cancer Research, ISSN 2156-6976, 2016, Volume 6, Issue 10, pp. 2235 - 2251
Advanced or recurrent low-grade serous ovarian cancers (LGSC) are resistant to conventional systemic treatments. LGSC carry mutations in RAS or RAF, leading to... 
Gene mutations | MEK inhibitors | ERK1/2 phosphorylation | Low-grade serous ovarian cancer | MAPK signalling | Cell line models | Copy-number alterations | PROTEIN-KINASE PATHWAY | BORDERLINE TUMOR | copy-number alterations | cell line models | MUTATION STATUS | THERAPY | NEOADJUVANT CHEMOTHERAPY | ONCOLOGY | BRAF MUTATIONS | PERITONEUM | gene mutations | KRAS | CARCINOMA | EXPRESSION
Journal Article
Gynecologic Oncology Reports, ISSN 2352-5789, 08/2018, Volume 25, pp. 41 - 44
Management of advanced/recurrent low-grade serous ovarian carcinoma (LGOSC) is often challenging. Effective treatment options remain limited for hormone and... 
Treatment-resistant | Serous | Recurrent | Binimetinib | MEK162 | Low-grade ovarian cancer
Journal Article